含有Apolipoprotein E的高密度脂蛋白与动脉硬化斑块的进展独立相关
在PubMed上查看摘要
概括
此摘要是机器生成的。含有Apolipoprotein E的高密度脂蛋白胆固醇 (APOE- HDLC) 可能表明动脉样硬化风险降低. 较高的APOE-HDLC水平与较慢的斑块进展有关,这表明它具有作为抗动脉增生生物标志物的潜力.
科学领域
- 心血管研究
- 脂肪新陈代谢
- 生物标志物发现
背景情况
- 高密度脂蛋白胆固醇 (HDLC) 以其抗动脉增生性质而闻名.
- 含有Apolipoprotein E的HDLC (APOE-HDLC) 越来越被认为是HDLC的关键功能组成部分.
- 关于APOE- HDLC在人类动脉样硬化的直接作用的数据有限.
研究的目的
- 研究APOE-HDLC水平与动脉样硬化斑块在人类中的进展之间的关联.
- 确定APOE-HDLC是否是动脉样硬化发展的独立预测因素.
主要方法
- 研究了没有心血管疾病的823名参与者 (年龄在45-74岁之间).
- 基线测量包括使用NMR光谱的HDLC颗粒度,APOE-HDLC水平和HDLC水平.
- 在5年间 (2002年至2007年) 使用心血管超声波来评估斑块的进展.
主要成果
- APOE- HDLC/ HDLC比率与5年后斑块进展的减少显著相关 (RR=0. 71).
- 这种关联仍然是显著的,并且独立于HDLC与HDL颗粒数比 (HDLC/P).
- 具有高APOE-HDLC/HDLC比率和低HDLC/P比率 (表明功能障碍的HDL) 的参与者显示斑块进展的风险降低了36%.
结论
- APOE-HDLC显示出其作为一种新生物标志物的潜力,用于评估HDL颗粒的抗动脉硬化功能.
- 这些发现支持含有APOE的HDL在减轻动脉样硬化的作用.
- 需要进一步的研究来验证APOE-HDLC作为临床生物标志物.
相关概念视频
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Overview
In response to tissue injury and infection, mast cells initiate inflammation. Mast cells release chemicals that increase the permeability of adjacent blood capillaries and attract additional immune cells to the wound or site of infection. Neutrophils are phagocytic leukocytes that exit the bloodstream and engulf invading microbes. Blood clotting platelets seal the wound and fibers create a scaffold for wound healing. Macrophages engulf aging neutrophils to end the acute inflammatory...
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...

